echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 86 varieties meet the requirements of the fifth batch of centralized procurement or become the first batch of special procurement products

    86 varieties meet the requirements of the fifth batch of centralized procurement or become the first batch of special procurement products

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, relevant departments organized a work conference on centralized drug procurement in Nanjing.


    Insulin may become the first batch of "special purchases" products.


    In addition, there are also news that biologics and proprietary Chinese medicines have entered mass purchases, and the accuracy of the news is not yet clear.


    It is reported that there are currently 86 varieties that meet the fifth batch of centralized procurement rules, including 33 injection varieties, 3 biosimilar drugs and multiple insulin varieties.


    The three biosimilar drugs that are eligible for collection are adalimumab, bevacizumab, and rituximab.


    As for the key insulin products that this centralized procurement focuses on, there are currently a number of domestic manufacturers of 3 or more (mainly concentrated in the second and third generation insulins).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.